Background Bevacizumab has been suggested to have similar eff ectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and diff erent regimens. Here, we report the fi ndings at the prespecifi ed 2-year timepoint.
Introduction
Neovascular age-related macular degeneration is a common bilateral condition that aff ects people aged 50 years and older, and causes severe impairment of central vision. Intravitreal treatment with ranibizumab, an anti body to vascular endothelial growth factor (VEGF), was shown to be eff ective in neovascular agerelated macular degeneration compared with photodynamic therapy or no treatment. 1, 2 Anti-VEGF drugs were thus established as a standard of care for neovascular age-related macular degeneration. [3] [4] [5] [6] Bevacizumab, an antibody to VEGF that is licensed for treatment of bowel cancers, is the parent molecule from which ranibizumab was developed. Small non-ran domised studies [7] [8] [9] done while ranibizumab was awaiting marketing authorisation suggested that bevacizumab had similar eff ectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. These fi ndings were important, because every dose of rani bizumab is expensive and treatment can be needed every month for several years. [3] [4] [5] [6] The dose at which bevacizumab is supplied is suffi ciently large to allow aliquoting into many smaller fractions for intra ocular administration, thus off ering large cost savings. Its use off licence, given in a similar way to ranibizumab, has spread rapidly across the world.
The absence of robust information about the safety of bevacizumab in the treatment of neovascular age-related macular degeneration and uncertainty about treatment frequency for both bevacizumab and ranibizumab led us to undertake the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial in the UK. 4 The Comparison of Age-related macular degeneration Treat ments Trials (CATT) were developed in parallel in the USA. 3, 5 We reported an interim analysis after 1 year of followup in 2012, and a pooled analysis of the IVAN and CATT 1-year data. 4 These analyses showed that functional outcomes were similar between the two drugs and between monthly (continuous) and intermittent treatment administration (as needed or discontinuous) but that the risk of a systematic serious adverse event (SAE) was higher with bevacizumab than ranibizumab. Here, we report the defi nitive fi ndings of the IVAN trial at the prespecifi ed primary 2-year timepoint and meta-analyses pooling key outcomes from both trials after 2 years.
Methods

Study design and participants
We undertook a multicentre, 2×2 factorial, non-inferiority randomised trial in 23 teaching and general hospitals in the UK (appendix). Full inclusion and exclusion criteria have been reported previously. 4 Briefl y, adults aged at least 50 years with active, previously untreated neovascular age-related macular degeneration in the eye designated as the study eye and a best corrected distance visual acuity (BCVA) of at least 25 letters on a standard vision chart were eligible to participate. 4 Participants provided written informed consent. A UK National Health Service Research Ethics Committee approved the trial (07/NIR03/37).
Randomisation and masking
Participants were randomly assigned (1:1:1:1) to one of four groups in a factorial design: ranibizumab or bevacizumab in continuous or discontinuous regimens. Randomisation was stratifi ed by centre and was blocked to ensure roughly equal numbers of participants per group within a centre. Allocations were computer generated and concealed with an internet-based system (Sealed Envelope, London, UK). Staff in participating centres accessed the website and, on entering information to confi rm a participant's identity and eligibility, were provided with the unique study number. Study participants and clinical assessors (nurses, optometrists, imaging technicians, and clinicians) were masked to drug allocation. Study drugs were dispensed by pharmacy staff who were unmasked, but had no other role in the study. Most IVAN sites used a separate unmasked clinical team consisting of a nurse and a clinician to administer treatment; this team did not take part in any other study procedures. At nine sites, staff were insuffi cient to have masked and unmasked teams; here, an unmasked nurse withdrew ranibizumab from the vial into a syringe so that the fi nal appearance of the preparation was identical to that of the syringe containing prefi lled bevacizumab.
All random allocations, including to continuous or discontinuous treatment, were prepared at the outset. Allocation to continuous or discontinuous treatment was masked up to 3 months, at which point both investigator and participant were unmasked. Lesion morphology was assessed by independent graders, who were masked to drug and treatment regimen, in the UK Network of Ophthalmic Reading Centres.
Procedures
Participants received intravitreal injections of ranibizumab (0·5 mg) or bevacizumab (1·25 mg).
2,10,11 Both drugs were procured commercially. The compounding pharmacy at the Royal Liverpool and Broadgreen University Hospitals NHS Trust (Liverpool, UK) was contracted to supply the study drugs. Bevacizumab was purchased from Roche and prepared for intraocular administration. The pharmacy used a range of standard and non-standard tests to establish stability, potency, and sterility of bevacizumab after aliquoting or storage, or both. 12, 13 Because the most convenient method of dispensing aliquoted bevacizumab is in a prefi lled syringe, the drug was stored in sterile polycarbonate syringes, secured with Luer-Lok tip caps for up to 90 days at a temperature of 2-8°C. Stability of the drug was confi rmed by tests of molecular weight and electric charge by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under non-denaturing and denaturing conditions, reverse-phase high-performance liquid chromatography, and size exclusion chroma tography. ELISA was used to confi rm binding of the drug to VEGF after storage. Tests were done to simulate conditions of transportation, in which syringes were shaken vigorously for up to 6 h at room temperature. The stored drug was subjected to micro scopic analysis and culture for microorganisms by serial sampling. The results showed that the drug remained stable and sterile under the conditions described. The pharmacy followed strict standard operating procedures and guidelines for manufacture that were submitted to and approved by the UK Medicines and Healthcare products Regulatory Agency.
Participants underwent clinical examination, optical coherence tomography (OCT), and fundus photography every month (28-35 days) . They received study injections at visits 0, 1, and 2. Participants assigned to the continuous regimen were treated monthly thereafter. Participants assigned to the discontinuous regimen were not retreated after visit 2 unless prespecifi ed clinical and OCT criteria for active disease were met. 4 If retreatment was needed, a further cycle of three doses was given monthly. Prompted by the fi ndings from CATT at 2 years, 5 colour and OCT images at baseline and most recent available follow-up were regraded after the end of follow-up, specifi cally to identify any new geographic atrophy lesions that had developed during the trial. Participants were followed up for 2 years. Exit visits before 2 years occurred only when a participant chose to See Online for appendix leave the study early or was withdrawn by a participating ophthalmologist.
Our objective was to test the non-inferiority of bevacizumab to ranibizumab and of the discontinuous to the continuous regimen. The primary outcome was BCVA (number of letters read on a standard early treatment diabetic retinopathy study chart at 2 years
14
). Secondary outcomes were additional visual function measures (contrast sensitivity, 15 near visual acuity, 16 and reading index 17 ), lesion morphology and metrics from angiograms and OCTs, generic and vision-specifi c health-related quality of life (EQ-5D, 18 MacDQoL, 19 and MacTSQ 20 ), adverse events, cumulative resource use or cost and costeff ectiveness, and survival free from treatment failure. Results of the cost analyses and for survival free from treatment failure will be reported elsewhere.
BCVA was measured every 3 months. Most of the other outcomes were measured at baseline and visits 3, 6, 12, 18, and 24. Lesion area was measured at baseline, and visits 12 and 24. EQ-5D was measured at baseline, and visits 3, 12, and 24. MacDQoL and MacTSQ were measured at visits 3, 12, and 24.
Adverse events were recorded at each visit and coded with the Medical Dictionary for Regulatory Activities (version 14.1). All SAEs were reviewed by senior clinicians (UC, SPH, SMD, and AJL), who were masked to treatment allocation. The primary safety outcome was the occurrence of an arterial thrombotic event (as defi ned by the Antiplatelet Trialists' Collaboration 21 ) or hospital admission for heart failure.
Statistical analysis
We specifi ed a non-inferiority limit of 3·5 letters for distance BCVA, assuming no interaction between drug and treatment regimen. The target sample size was 600, which would give 90% power to detect non-inferiority (signifi cance 2·5%, one-sided). 4 Modifi ed intention-to-treat analyses were directed by a pre specifi ed analysis plan. All participants who received at least one dose of allocated drug were included in analyses. We compared drugs and dosing regimens with logistic regression (binary variables) and linear mixed model regression (continuous variables), except when otherwise noted. Analyses were adjusted for centre size (seven strata), combining adjacent strata if necessary to ensure estimation. For continuous variables measured at baseline, we modelled values jointly to avoid having to exclude or impute cases with missing baseline measures. We fi tted interactions with follow-up time and describe diff erences between groups at 2 years. We checked model validity with recommended graphical methods. 22 When a model fi tted poorly, we explored transformations. Outcomes analysed on a logarithmic scale were trans formed back to the original scale after analysis and results are presented as geometric mean ratios. Odds ratios were used for comparisons of EQ-5D, lesion area, and MacTSQ at 2 years, for which we were unable to identify a suitable trans formation; we dichotomised data and adjusted analyses for baseline value when obtained. We compared num bers of SAEs by drug and treatment regimen when more than ten participants experienced the event. We used likelihood ratio tests to establish signifi cance.
Results are reported as eff ect estimates with 95% CIs. We report comparisons between drugs separately for continuous and discontinuous regimens only when the interaction of drug and dosing regimen reached a prespecifi ed level of signifi cance (5% for total lesion thickness at the fovea and presence of fl uid on OCT, for which CATT suggested a possible interaction; 3 1% otherwise).
Previous meta-analyses have been reported. 23, 24 We adapted the search strategy used by Mitchell 24 (who identifi ed one head-to-head trial report ing outcomes to 1 year 25 ) and noted that 2-year fi ndings were reported only for CATT. 5 We combined changes in BCVA at 2 years from baseline in CATT and the IVAN trial in a fi xedeff ects meta-analysis. We used weighted mean diff erences to account for study size. We investi gated mortality, arterial thrombotic events, occur rence of at least one serious adverse event, which were all avail able to only 1 year by treatment regimen for CATT. Additionally, we investigated change in total lesion thickness at the fovea, and new geographic atrophy. We combined changes because the primary CATT analyses reported change analyses. The analyses of the safety data and geographic atrophy used raw frequency counts.
Analyses were done with Stata (version 12.1) and SAS (version 9.3).
This trial is registered, number ISRCTN92166560.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between March 27, 2008, and Oct 15, 2010, we randomised 628 patients to ranibizumab or bevacizumab. 18 were withdrawn, leaving 610 who received the study drugs and were included in analyses (appendix). Participants' baseline characteristics were similar across the groups (appendix). Nine participants were identifi ed as ineligible after images submitted at time of recruitment were graded, but were nevertheless included. 4 Ophthal mologists reported not knowing which drug participants were receiving at visit 3 on 555 (98%) of 567 occasions, at visit 12 on 514 (99%) of 521 occasions, at visit 24 on 506 (99%) of 512 occasions, and at exit visit on all 22 occasions. Participants reported not knowing which drug they were receiving at visit 3 on 560 (99%) of 564 occasions, at visit 12 on 509 (99%) of 516 occasions, at visit 24 on 499 (98%) of 510 occasions, and at exit visit on all 21 occasions. Some protocol deviations were recorded (appendix). The wrong study drug was given on two (<1%) of 12 761 follow-up visits, and treatment regimens were not adhered to on 133 visits (1%). Overall, 350 participants (57%) missed at least one visit, including those who died or withdrew early. However, 12 761 (87%) of 14 640 scheduled visits were attended, and the analysis methods meant that most participants could be included.
525 participants reached the visit at 2 years (table 1) . BCVA at 2 years was similar between ranibizumab and bevacizumab groups and con tinu ous and discontinuous treatment groups (table 1) . Bevacizumab was neither inferior nor non-inferior to ranibizumab because the 95% CIs include zero and the non-inferiority margin (fi gure 1). Similarly the discontinuous regimen was neither inferior nor non-inferior to the continuous regimen. Therefore, the primary hypotheses about the non-inferiority of dis continuous bevacizumab to continuous ranibizumab were not supported.
Near visual acuity, reading index, and contrast sensitivity after 2 years did not diff er signifi cantly between drug groups (fi gure 2, table 1). However, near visual acuity and contrast sensitivity were signifi cantly worse with the discon tinuous regimen (fi gure 2, table 1). Total EQ-5D score † † † 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00) 0·85 (0·73 to 1·00) Data are mean (SD), median (IQR), or n/N (%). 525 patients who reached visit 24 at 2 years included, unless otherwise stated. *Data missing for eight patients (one given ranibizumab in continuous regimen; two given ranibizumab in discontinuous regimen; one given bevacizumab in continuous regimen; four given bevacizumab in discontinuous regimen). †All study participants (n=610) included in analysis. ‡Data missing for 26 patients (six; nine; fi ve; six). §Data missing for 41 patients (nine; 13; seven; 12). ¶Log(minimum angle of resolution)=1·6. ||Data missing for 21 patients (four; seven; four; six). **Data missing for 30 patients (six; 11; eight; fi ve). † †Data missing for 30 patients (six; 11; eight; fi ve). ‡ ‡Data missing for 26 patients (six; nine; six; fi ve). § §Data missing for 39 patients (nine; 12; eight; ten). ¶ ¶Includes lesions with zero area (ie, not present); data missing for 45 patients (11; 14; nine; 11). ||||Number of eyes with non-zero lesion area. ***Data missing for 14 patients (six; three; one; four). † † †Data missing for 11 patients (two; two; three; four). ‡ ‡ ‡Score ranges from −9 (maximum negative eff ect) to 3 (maximum positive eff ect); data missing for 91 patients (25; 20; 24; 22) . § § §Score ranges from 0 to 72 (higher scores indicate higher satisfaction with treatment); data missing for 107 patients (29; 22; 28; 28) . Data are n or n (%). MedDRA=Medical Dictionary for Regulatory Activities. *Two in bevacizumab discontinuous group occurred >3 months after last visit. †One in bevacizumab discontinuous group occurred >3 months after last visit. ‡Not defi ned as an expected serious adverse event in the protocol. §Includes any non-ocular serious adverse event. ¶One in bevacizumab discontinuous group occurred >105 days after last visit. ||Three in bevacizumab discontinuous group occurred >105 days after last visit. **One in bevacizumab discontinuous group occurred >105 days after last visit. † †One in bevacizumab discontinuous group occurred >105 days after last visit. ‡ ‡One in ranibizumab discontinuous group occurred >105 days after last visit. Tests of the frequency of SAEs in diff erent organ systems when there were more than ten participant-specifi c events showed that SAEs coded as general disorders and adminis tration site conditions (which includes all deaths) diff ered by treatment regimen (p=0·03) but not for any other organ system by drug or treatment regimen (table 2, appendix). SAEs coded as gastrointestinal were more frequent with bevacizumab than with ranibizumab (table 2), but the diff erence was not signifi cant (p=0·06; appendix) and was less than at 1 year. 4 Serious ocular adverse events were rare (table 2, appendix).
The BCVA point estimate with pooled IVAN and CATT data showed that bevacizumab was non-inferior to ranibizumab, judged by the strict IVAN non-inferiority margin of 3·5 letters (fi gure 3). Although the as needed treatment regimens diff ered slightly, we decided to pool data for the two trials for this comparison. The discontinuous regimen was inferior to the continuous regimen (fi gure 3). Pooled estimates of changes in total lesion thickness at the fovea showed no diff erence between drugs, but favoured continuous treatment (p=0·001; appendix). New geographic atrophy was detected significantly more often during follow-up in participants on continuous than dis continuous regimens, but no diff erence between drugs was recorded (p=0·001; fi gure 4). Pooled estimates of safety outcomes showed no diff erences by drug for deaths or arterial thrombotic events but a signifi cantly increased risk of any systemic SAE for bevacizumab (p=0·008; fi gure 5). The com parison by regimen showed consistent increases in mortality (p=0·014) and the risk of any systemic SAE (p=0·063) with discontinuous treatment across trials (fi gure 5).
Discussion
After 2 years in the IVAN trial, neither the comparison of bevacizumab with ranibizumab nor that of continuous with discontinuous regimens for BCVA was conclusive when judged against the prespecifi ed non-inferiority margin of 3·5 letters. However, the mean diff erences between groups, tending to favour ranibizumab and continuous treatment, were small and estimated to within 2·4 letters. Non-inferiority for both comparisons would have been established had we used the CATT non-inferiority margin of 5 letters. When we examined the pooled IVAN and CATT fi ndings for BCVA, the point estimates were consistent. The increased precision gained with pooled data showed that bevacizumab was non-inferior to ranibizumab, but that discontinuous treatment was inferior to continuous treatment (panel). Nevertheless, even in the comparison between treatment regimens, the pooled mean diff erence was small from a clinical perspective. With respect to lesion morphology, we identifi ed no signifi cant diff erences between drugs at 2 years, but consistent diff erences favouring continuous treatment. The meta-analysis of total lesion thickness at the fovea confi rmed these fi ndings. Similar to the lesion metrics, we recorded no diff erences in quality of life by drug, but near visual acuity and contrast sensitivity favoured a continuous regimen. Overall, the fi ndings for the IVAN secondary visual function outcomes and the pooled fi ndings for BCVA and lesion morphology consistently show that bevacizumab has similar effi cacy to ranibizumab. The fi ndings also suggest that continuous treat ment every month gives slightly better visual function than does discontinuous treatment, although this improvement was not refl ected in the primary outcome of BCVA or in self-reported health-related quality of life.
The CATT 2-year report 5 suggested diff erences between drugs and treatment regimens in the development of new geographic atrophy in the study eye during followup. We found no diff erence between drugs in the IVAN trial alone and when CATT and IVAN data were combined. However, our analysis showed a consistent and sub stantial increase in the risk of developing new geo graphic atropy with monthly compared with discontinuous treat ment. This fi nding raises the worrying possibility that any visual benefi t from monthly treatment might not be maintained in the long term.
For safety outcomes, our fi nding that mortality was higher at 2 years with discontinuous treatment than continuous treatment is similar to the 1-year fi ndings in CATT (pooled OR 0·49; p=0·014), as is increase in the risk of any systemic SAE (0·81; p=0·063). The comparisons of discontinuous and continuous regimens were not masked in either trial, but it seems implausible that bias should lead to an increased frequency of SAEs with discontinuous treatment. These worrying fi ndings appear counter intuitive when viewed in a conventional dose-response framework. However, in the context of biological therapies, the possibility of immunological sensitisation with intermittent dosing needs to be considered. 28 Neither the IVAN trial nor CATT was powered to detect diff erences in harms of treatment. Hence, the meta-analyses provide the best summary of the available data. The comparisons between the drugs after 2 years are reassuring, with no suggestion of any diff erence in mortality or arterial thrombotic events, which have pre viously been suggested to be related to use of anti-VEGF drugs. The pooled analysis for any systemic SAE seems to confi rm an increased risk with bevacizumab, which was fi rst reported in CATT. 3, 5 However, the pooled analysis disguises the inconsistency between the separate trial estimates. Although the trials had similar fi ndings at 1 year, 4 the SAEs accruing in the second year in the IVAN trial shifted the 2-year OR almost to unity. Other fi ndings for cardiovascular arterial thrombotic events from large analyses of routinely obtained data also vary [29] [30] [31] and are at risk of confounding. 32 Diff erences between trials in masking of participants to drug allocation, which was achieved reliably only in the IVAN trial, could be a possible explanation. The accruing SAEs in our trial also provided improved precision for the pooled comparison by treat ment regimen (IVAN 2-year and CATT 1-year data), showing a signifi cant diff erence in mortality favouring continuous treatment, which is probably the fi nding of greatest concern. Our trial has important strengths. It was pragmatic, being done in the usual care setting in many hospitals in the UK National Health Service, and so directly informs the use of anti-VEGF drugs in similar settings. The bevacizumab product used in this trial was sourced from a compounding pharmacy that aliquoted and dispensed the drug, adhering to protocols for tests of potency and sterility approved by the Medicines and Healthcare products Regulatory Agency. Our fi ndings should be generalised only to bevacizumab sourced from a manufacturing pharmacy that has quality-control processes to validate stability, potency, and sterility that have been approved by a drug regulatory agency.
The factorial design was effi cient and provided high statistical power for the primary outcome, despite the fact that the IVAN trial had only half as many participants as CATT. We studied a range of secondary functional outcomes that both support the visual acuity fi ndings and describe the compromises when treatment is not continuous. We assessed the resources used to adminis ter treatment and previously reported that they were similar with either drug. 4 Drug allocation was success fully masked and, in view of the elderly trial population, we had good retention. Sites failed to comply with the allocated treatment on only roughly 1% of visits (almost always relating to the treatment regimen) and, although most patients missed one or more visits, missed visits did not diff er by group and most scheduled visits were attended.
The interpretation of the meta-analyses is limited by the appropriateness of pooling of available trials. 33 We argue that, in this instance, the pooling of data was appropriate, because the studies were planned to be similar in design. We described our intention to pool data from the two trials in advance, and the CIs for the estimates from the studies overlap in all reported metaanalyses. The meta-analyses of safety particularly were prompted by the IVAN and CATT data monitoring committees. Our descriptions of results from the two trials as consistent or inconsistent are subjective judgments on the basis of the meta-analysis graphs.
Anti-VEGF drugs look set to remain the mainstay treatment for neovascular age-related macular degeneration for the foreseeable future, despite the rapid increase in potential new treatments. Concerns have been raised about the safety of afl ibercept, 34 despite evidence of effi cacy, 6 and the results of brachytherapy in combination with anti-VEGF drugs have, so far, been disappointing. 35 Photodynamic therapy or radiotherapy options used in combination might yet allow reductions in treatment frequency, but it will be important to study these treat ment strategies in comparison with monthly treatment, in view of our fi nding of possible risks of discontinuous treatment.
In conclusion, the IVAN trial and meta-analyses of the CATT and IVAN data show that the choice of anti-VEGF treatment strategy is less straightforward than previously thought. Bevacizumab and ranibizumab have similar effi cacy and can be considered equivalent in this respect in the treatment of neovascular age-related macular degeneration. The increased risk of systemic SAEs and death with discontinuous treatment should probably outweigh the increased risk of new geographic atrophy that was recorded with monthly treatment. The slightly better functional outcomes with continuous treatment are a bonus. Continuous treatment also avoids the need to monitor disease activity on every visit. An important consideration when choosing to give treatment continuously is the high cost of ranibizumab, 4 which may be unaff ordable for publicly funded health systems.
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Panel: Research in context
Systematic review
We searched PubMed for reports of previous head-to-head trials with the terms "ranibizumab" (MeSH term or text), "bevacizumab" (MeSH term or text), and "macular degeneration" (major MeSH term), published in any language before July 3, 2013. We included only clinical or randomised controlled trials and identifi ed systematic reviews comparing ranibizumab and bevacizumab. We searched Current Controlled Trials across several trial registers ("macular degeneration" and "ranibizumab", "bevacizumab", or "VEGF" in the title). We identifi ed three trials other than CATT and the IVAN trial in which bevacizumab and ranibizumab have previously been compared. [25] [26] [27] Two were single-centre trials 25, 27 and one a multicentre trial (the MANTA study 26 ), but fi ndings at 2 years had not been reported. Therefore, we only included the CATT and IVAN data in our meta-analyses.
Interpretation
IVAN and CATT are the fi rst and largest multicentre head-to-head trials in which bevacizumab and ranibizumab for neovascular age-related macular degeneration have been compared. After 2 years in the IVAN trial, the comparisons of the eff ect of the drugs and of discontinuous versus continuous treatment on best corrected visual acuity were inconclusive. However, when we pooled data from the two trials, bevacizumab was non-inferior to ranibizumab. It is now established that bevacizumab is not inferior to ranibizumab after 2 years of either continuous or discontinuous treatment with respect to visual acuity, and that total lesion thickness is also not signifi cantly diff erent by drug. With respect to systemic safety, there is no suggestion of any diff erence between drugs in deaths or arterial thrombotic events at 2 years. As far as we are aware, visual function and safety with continuous versus discontinuous treatment has been compared only in CATT and the IVAN trial. Pooled data from the two trials shows that discontinuous treatment was inferior to continuous treatment for best corrected visual acuity. However, this diff erence is not clinically important. There was a signifi cant diff erence in mortality favouring continuous treatment. Conversely, the risk of geographic atrophy increased with continuous treatment. The trade-off s should be discussed with patients. Overall, the available data show that the choice of anti-VEGF treatment strategy for neovascular age-related macular degeneration is less straightforward than previously thought. Bevacizumab and ranibizumab have similar effi cacy, but the diff erence in mortality favouring continuous treatment means that continuous treatment might be preferable. adverse events. LAC was the trial manager and implemented the trial protocol, developing and refi ning trial procedures to optimise its conduct. UC, CAR, and BCR wrote the fi rst draft of the report. All authors contributed to the fi nal draft and approved its submission for publication.
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